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Drit.J. Psycho!. med. Sect. 42, 1 (190b) Brit. J. prev. soc. Med. 23, 244 (1970) Brit.J. Psychiat. 116, 281,289,299,307 (1971)ActCpsychIat. scwid. (in press) Brown F (1966) Brit. J. Psychiat. 112, 1035 Meeting May 121970 .Do-?_---Leveis aind _ fect [Abridged] Dr C J S Waler (Herts and Essex General Hospital Bishops Stortford, Hertfordshire) Individual variation in the metabolism of drugs is important (Brodie 1964 , Price Evans 1965 yet relatively few reports attempting to relate plasma levels of antidepressants to their biological effects, both wanted and unwanted, have appeared. However, the rarity of such reports is not really surprising as it was not until the work of Moody et al. (1967) that a reliable method of extracting and estimating plasma imipramine became available. It is this inethod, with only minor modifications of technique, that has been used in this study.
Imipramine hydrochloride is readily absorbed from the intestine (Bernhard & Beer 1962) and in man it is metabolized along two major pathways: demethylation and hydroxylation (Herrmann 1963) . It has been suggested by Gillette et al. (1961) , Sulser et al. (1962) , and Brodie (1965) that the action of imipramine is mediated by its demethylated metabolite, desmethylimipramine (DMI). The highest tissue concentrations (suicide) of imipramine and its metabolites have been found in brain, lung, liver and kidney (Herrnann & Pulver 1960 , Curry 1964 , Dingell et al. 1964 ). Imipramine rapidly crosses the blood-brain barrier (Bickel & Weder 1969) and is thought to act within the CNS mainly through inhibiting reabsorption of monoamines. at storage sites (Axelrod et al. 1961) . Plasma levels are low and the tissue to plasma concentration ratios are of the order of 100: 1 (Bickel & Weder 1968) ; none the less, the plasma levels of imipramine are the best currently available index of drug concentration at the site ofactivity.
Clinically there would appear to be either no real difference between the effectiveness of imipramine and desmethylimipre (Rose & Westhead 1967) or some superiority of the former (Edwards 1965) . There is also a suggestion that in the rabbit DMI is methylated to imipramine in the lung and other tissues (Dingell & Sanders 1966) . Moreover, the finding of Hammer et al. (1969) that patients who show high plasma levels of one tricyclic antidepressant replicate similar levels with other such drugs may mean that a genetically determined mechanism, which is effective for a whole category of similar drugs, 
Mlaterial and Methods
To qualify for inclusion in the trial patients had to be diagnosed as suffering from endogenous depression of sufficient severity to warrant admission to hospital and to have received no previous medication. These criteria limited the numbers and the obvious weakness of the results is the small number of patients treated. Each patient was clinically assessed and rated on a diagnostic scale (Carney et al. 1965) , the level of depression was scored on the Hamilton scale (Hamilton 1960 ) and a self-rating made by the patient. Also before the start of treatment a sideeffects check list was compiled, the patient being asked directly for specific symptoms commonly attributed to the action of drugs (Table 1 ). The Hamilton scale, self-rating scale and side-effects check list were repeated at weekly intervals, but without reference to the previous assessments. At four weeks a final assessment of improvement or failure to improve was made; this took into account the clinical views of other doctors and nurses. The assessments were carried out in complete ignorance of the plasma imipramine levels which were estimated following a loading dose and then at weekly intervals.
Imipramine was administered orally in three divided doses and the plasma collected at weekly intervals with the patient fasting and between fourteen and fifteen hours after the last dose, the time interval being a conclusion drawn from work on loading doses of imipramine. Either a fixeddose regimen could be followed, as by Haydu et al. (1962) , or an attempt made to adjust the dose according to the weight of each patient. The latter scheme renders plasma levels of imipramine directly comparable between patients. Following Price Evans (1960, 1963) the principle of relating dosage to 'the metabolically active mass', which is calculated as weight07 (Drabkin 1959) , was adopted, an adjustment being made weekly as the patient's weight varied. To limit the influence of extraneous factors on the enzyme systems, for the duration of the trial, all other drugs were withheld except for nitrazepam 5-10 mg at night.
Results
These are based on a sample of 16 patients: 8 who entered and completed the trial, and a further 8 patients who, although similarly depressed, had not met the criteria for inclusion in the trial because of previous abortive treatment with other drugs and whose dosage of imipramine varied between 150 mg and 225 mg daily. There were 3 women and 5 men (sex ratio was identical in the two sub-groups), their average age was 44 years with a mean duration of symptoms of four months and a diagnostic index score of +7. With treatment the patients' mean scores on both the Hamilton scale and the self-rating scale fell uniformly by the end of the first week and again represented a similar degree of improvement at the end of four weeks. The correlation between the two scales was high (r+0-62, P< 0-001).
The mean pretreatment score on the side-effects check list was five, and throughout the first month of treatment it remained above that figure. There were two high points, one in the first week and a peak at the end of the third week. Plasma imipramine estimations gave values between 2 5 and 71 0 pg/1,000 ml; the mean values for weekly estimations were 27-3, 23-5, 22-2 and 33-8 pg/I ,000 ml. The relationship between these measures is an interesting one and all three show a biphasic appearance (Fig 1) .
However, when the patients were assessed at four weeks and divided into responders and non-responders, the five responders showed an 85 % reduction on the Hamilton scale, whereas the scores of the non-responders fell by only 17%. The self-rating showed a similar diffrc. Sideeffects had been elicited more often from the responders both at four weeks and also throughout the trial; apart from the first week of tetment th three who failed to respond ted to fewer si than at the p ant interview. Te weekly lIvs of plasma imipramine for therespondersandnon-responderswere24-6, 306, 25-6, 46-1 and 31-8, 11-7, 16-5, 13-3 pg/l,000 ml respectily. At four weeks all the responders showed evi s of more than 20-0 W/1,000 ml and all th non-rponders had values bedow that figure. Similar mlevels at the dtme of final assessmt, were obtained in the secondsub-group and all ndes (10) had plasma imipramine levels of more than 20-0 pg/l,000 ml and all nonresponders (6) showed plasma levels bdow that figure. Table 2 shows the difference between the two groups at four weeks. The differences, apart from the sideeffects score, are significant eve in these very small numbers. However, once an adjtetment is made to allow for the pretromnt 'side-effects' ofimipramine the dff the, two groups also reaches a significant level. On poolingthedatathedifferencesaremaintained, also a high negtive correlation between plasma imipramine levelsand Hamilton scale scores (r-0-73, P <0-01), and a similarly important positive correlation between plasma imipramine levejs and incidence of side-effects (r+0-52, P<0-05) is demonstrated. Angst (1964) on the evidence of clinical studies suggested that-there may be mil rstant to inipranine, and such a genetic fator has now been confirmed by Alexandeon et al. ( 969) who investigated 'steady state' plasm levels of nortriptyline (NT) in twins. Hammer & Sjiqvist (1967) have put forward the hypothesis that an individual difference in the activity ofhydroxylating enzymes, leading to a low or high capacity for hydroxylation of tricyclic antdepressant, is the actual cause of the difference. It has also been shown by Hammer et al. (1966) , that barbiturates may plasma levels of DMIby increasing the activity of hydroxylating enzymes in the liver microsomes. Thus response to a tricyclic antideesant might be a factor of the indiidual's genetc make-up combined with the environmental influence of other drugs.
Discussion
The published reports on plasma levels of antideprsnts have prhaps tended to concentrate on the biohmical method employed, to the detiment ofclinial T.The seection and clinical m t of paIen has beon vague. although they report on the larest number of cas, refer to them merely as 'hospitalized patiets with various types of deessi and when relating t high plasma levels of drugs to severity of sideoffects do not enhrw on whether the sid eics were elicited by muns of direct questions or volunteered y. Maxwell & Rose (1970) , although not ding with plasma levels, at ed to rlate n scores with sponItneousy reported side-ffects, but obtid pr agre nt. his is probably because they tied to compae two mehodolog"ily diffrent _ t scales. As rating-methods of judging depression are now acceped -and used, a side-effects check list is essential. With careful selection and assessment of patients on both depressive and side-effects scales a possible relationship between plasma imipramine levels and both clinical outcome and incidence of sideeffects has been demonstrated. The summarized results (Table 3 ) are in agreement on the relationship of sideeffects to plasma levels, but not on the relationship of plasma levels to clinical response. Bickel & Weder (1968) stress that imipramine is easily absorbed and reaches tissues rapidly. Fig  I shows a phasic pattern and this occurs not only in the plasma imipramine levrels but also embraces the other results which are thought to reflect the effect of variation of plasma imipramine levels. Mean plasma levels reach a high point at the end of the first week and a peak in the fourth, the group of responders shows rises in the second anid fourth weeks, whereas the non-responders have their highest values in the first and third weeks. The same biphasic pattern is demonstrated following a single loading dose of imipramine (Fig 2) . This would suggest that the fluctuations of plasma imipramine levels, until a steady state has been reached, might be responsible for the side-effects.
Summary
Results from a group of endogenously depressed patients suggest a relationship between high 'steady state' plasma imipramine levels and a favourable outcome of depression. Also a similar relationship between high plasma imipramine levels and increased frequency of side-effects is found.
Dr Stephen H Curry (Department ofPharmacology and Therapeutics, London Hospital Medical College, London El) Chlorpromazine: Concentrations in Plasma, Excretion in Urine and Duration ofEffect The absorption, metabolism and excretion of chlorpromazine has interested many investigators in the last twenty years, but only recently has it been possible to study concentrations of the compound in plasma. Studies of such concentrations, with a variety of compounds, have been delayed by the lack of suitable chemical methods of drug analysis. The recent availability of ultramicro methods has coincided with an increasing interest in drug concentrations, especially where centrally-
